ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani Sells 33,481 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani sold 33,481 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total value of $1,941,563.19. Following the sale, the chief executive officer now directly owns 370,378 shares in the company, valued at $21,478,220.22. The trade was a 8.29 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

ANI Pharmaceuticals Stock Up 2.6 %

ANIP stock opened at $59.39 on Friday. The firm has a market cap of $1.25 billion, a PE ratio of -107.98 and a beta of 0.71. ANI Pharmaceuticals, Inc. has a 12 month low of $48.20 and a 12 month high of $70.81. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The firm has a 50 day simple moving average of $58.28 and a 200 day simple moving average of $60.75.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. The company had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.05 EPS. Equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ANIP. Piper Sandler assumed coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 price target on the stock. Raymond James boosted their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. StockNews.com lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. HC Wainwright reissued a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Finally, Truist Financial increased their price target on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $77.33.

Institutional Trading of ANI Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Pacer Advisors Inc. increased its position in shares of ANI Pharmaceuticals by 23,259.8% in the third quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock worth $33,907,000 after acquiring an additional 565,910 shares in the last quarter. Bank of Montreal Can acquired a new position in ANI Pharmaceuticals in the 3rd quarter worth approximately $13,043,000. Millennium Management LLC grew its position in ANI Pharmaceuticals by 1,005.8% during the 2nd quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock worth $14,651,000 after purchasing an additional 209,272 shares in the last quarter. Mizuho Markets Americas LLC acquired a new stake in ANI Pharmaceuticals during the 3rd quarter valued at $11,670,000. Finally, Barclays PLC lifted its holdings in shares of ANI Pharmaceuticals by 1,681.2% in the third quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company’s stock valued at $8,534,000 after purchasing an additional 135,003 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.